Ganciclovir Chemoablation of Herpes Thymidine Kinase Suicide Gene-Modified Tumors Produces Tumor Necrosis and Induces Systemic Immune Responses
- 20 September 1998
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 9 (14) , 2019-2030
- https://doi.org/10.1089/hum.1998.9.14-2019
Abstract
The goal of this work was to identify potential host immune responses to thymidine kinase (TK) suicide gene-modified tumors undergoing chemoablation induced by the prodrug ganciclovir (GCV). The aims were to measure the efficacy and specificity of immunity induced against unmodified tumor, to identify qualitative or quantitative changes in the host response to TK+ tumors undergoing chemoablation that may contribute to the induction of antitumor immunity, and to compare critically the induction of immunity by chemoablation of TK-modified tumors with that of other methods of immunization in this tumor model and in response to other well-defined model antigens. Animals treated with TK+ tumors and GCV developed specific resistance to rechallenge with unmodified tumor. GCV induced significant tumor necrosis, which was associated with a pronounced host cell infiltrate composed of polymorphonuclear cells, both CD4+ and CD8+ T lymphocytes, and increased intratumoral IL-12. Cyclophosphamide-treated mice exhibited no such host response despite the induction of tumor necrosis. CTL responses to defined antigens in TK+ cells were greater in animals treated with prodrug than were those in animals not treated with prodrug but harboring live TK+ cells. Similar degrees of immunity were produced by immunization with irradiated cells. Transfer of metabolic suicide genes to tumors and subsequent treatment with prodrug can induce tumor regression in vivo. The antitumor effect is explained largely by the activation of prodrug in the tumor, but an immunological host response to the process may also occur. This work explores the immunological consequences of ganciclovir prodrug ablation of tumor cells modified to express the herpes simplex thymidine kinase gene. Induction of immunity to unmodified tumor, as well as to two defined model antigens on the tumor, was detected. Treatment induced tumor necrosis and a host response consisting of both CD4+ and CD8+ T cells, polymorphonuclear cells, and IL-12. Such a host response was not seen in animals treated with cyclophosphamide, a commonly used anticancer drug.Keywords
This publication has 22 references indexed in Scilit:
- The Role of Interleukin-2 in Combination Adenovirus Gene Therapy for Head and Neck CancerMolecular Endocrinology, 1997
- Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatmentGene Therapy, 1997
- Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancerInternational Journal of Cancer, 1997
- Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapyJournal of Neurosurgery, 1996
- Effect of Freund's adjuvants on guinea pigs infected with, or vaccinated against, Trichostrongylus colubriformisInternational Journal for Parasitology, 1996
- Cure of Mice with Established Metastatic Friend Leukemia Cell Tumors by a Combined Therapy with Tumor Cells Expressing Both Interferon-α1 and Herpes Simplex Thymidine Kinase Followed by GanciclovirHuman Gene Therapy, 1996
- The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cellsCancer Letters, 1995
- Metabolic suicide genes in gene therapyPharmacology & Therapeutics, 1994
- Tolerance, Danger, and the Extended FamilyAnnual Review of Immunology, 1994
- Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells.The Journal of Experimental Medicine, 1982